Moreover, TMSB4X-derived peptides are being tested in clinical trials and have shown promising results for the treatment of ulcers and other slow-healing wounds (reviewed by Goldstein et al., 2012; Goldstein and Kleinman, 2015; Kleinman and Sosne, 2016). This evidence concerns the gene TMSB4X and ulcer disease.